衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)
Multiplex Assay Kit for Fibulin 3 (FBLN3) ,etc. by FLIA (Flow Luminescence Immunoassay)
EFEMP1; DHRD; DRAD; FBNL; MLVT; MTLV; S1-5; EGF-Containing Fibulin-Like Extracellular Matrix Protein 1; Fibrillin-Like; Extracellular protein S1-5
（注：单次混测多因子不超过8个指标 ）
- 编号LMF422Ra
- 物种Rattus norvegicus (Rat，大鼠)相同的名称，不同的物种。
- 实验方法双抗夹心
- 反应时长3.5h
- 检测范围0.05-50ng/mL
- 灵敏度最小可检测剂量小于等于0.017 ng/mL.
- 样本类型Serum, plasma, tissue homogenates and other biological fluids
- 下载英文说明书 中文说明书
- 规格8指标数7指标数6指标数5指标数4指标数3指标数2指标数1指标数
- 价格¥ 2845¥ 2955¥ 3119¥ 3338¥ 3557¥ 3885¥ 4378¥ 5472 添加到价格计算器 计算器
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
产品包装(模拟)
产品包装(模拟)
通过ISO 9001、ISO 13485质量体系认证
特异性
本试剂盒用于检测衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)，经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制，不可能完成对所有相关或相似物质交叉反应检测，因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)（加标样品），重复测定并计算其均值，回收率为测定值与理论值的比率。
| 样本 | 回收率范围(%) | 平均回收率(%) |
| serum(n=5) | 90-105 | 101 |
| EDTA plasma(n=5) | 83-97 | 86 |
| heparin plasma(n=5) | 83-91 | 88 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差：取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次，分别计算不同浓度样本的平均值及SD值。
批间差：选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定，每个样本使用同一试剂盒重复测定8次，分别计算不同浓度样本的平均值及SD值。
批内差： CV<10%
批间差： CV<12%
线性
在定值血清及血浆样本内加入适量的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)，并倍比稀释成1:2，1:4，1:8，1:16的待测样本，线性范围即为稀释后样本中衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)含量的测定值与理论值的比率。
| 样本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 97-104% | 81-97% | 78-90% | 85-99% |
| EDTA plasma(n=5) | 84-98% | 81-98% | 94-105% | 97-105% |
| heparin plasma(n=5) | 83-96% | 78-101% | 86-103% | 97-105% |
稳定性
经测定，试剂盒在有效期内按推荐温度保存，其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响，实验室的环境条件需尽量保持一致，尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本准备；
2. 加样（标准品、样本、磁珠）标准品或样本100μL及磁珠10μL，
37°C酶标板振荡器孵育90分钟；
3. 磁吸甩干，加检测溶液A100μL，37°C酶标板振荡器孵育60分钟；
4. 磁吸洗板3次；
5. 加检测溶液B100μL，37°C振动孵育30分钟；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋涡震荡2分钟后读数。
实验原理
将衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)抗体包被于磁珠，制成固相载体，向微孔中分别加入标准品或标本以及磁珠，其中的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)与连接于固相载体上的抗体结合，然后加入生物素化的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)抗体，将未结合的生物素化抗体洗净后，加入PE标记的亲和素，再次彻底洗涤后即可上机读数。MFI值和样品中的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)呈正相关。
赠品
增值服务
相关产品
| 编号 | 适用物种：Rattus norvegicus (Rat，大鼠) | 应用(仅供研究使用，不用于临床诊断！) |
| RPF422Ra01 | 衰老关键蛋白3(FBLN3)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAF422Ra01 | 衰老关键蛋白3(FBLN3)多克隆抗体 | WB; IHC; ICC; IP. |
| SEF422Ra | 衰老关键蛋白3(FBLN3)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMF422Ra | 衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
| 杂志 | 参考文献 |
| 1 | Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma[PubMed: PMC3761217] |
| Anticancer Res. | YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis.[Pubmed: 24324091] |
| Oncology Reports | Role of fibulin-3 in lung cancer: In vivo and in vitro analyses[Spandidos-publications: Source] |
| Current Pulmonology Reports | Discovery of new biomarkers for malignant mesothelioma[Springer:Source] |
| United States Patent Application 20140378336 | DIAGNOSIS OF CELL PROLIFERATIVE DISEASES[Freepatentsonline:Source] |
| Thorax. | Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma[Pubmed:Pmc4174124] |
| Egyptian Journal of Chest Diseases and Tuberculosis | Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions[Pubmed:23050525] |
| Radiol Oncol | Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma[PubMed: 26401134] |
| British Journal of Cancer | Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis[PubMed: 26263483] |
| J Thorac Oncol. | Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.[Pubmed:26903362] |
| BMJ Open | Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study [pubmed:27884852] |
| 25 | HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients[pubmed:26733616] |
| BMJ Journals | Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational …[e013324.abstract] |
| Anticancer Res. | Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.[pubmed:28314308] |
| Dis Markers. | A Novel Panel of Serum Biomarkers for MPM Diagnosis.[pubmed:28348450] |
| The Knee | Association of fibulin-3 concentrations with the presence and severity of knee osteoarthritis: A cross-sectional study[pubmed:29195846] |
| Disease markers | Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population[pubmed:29200597] |
| Molecular Medicine Reports | Placental protein 14 as a potential biomarker for diagnosis of preterm premature rupture of membranes[Pubmed:29749501] |
| Oncotarget | The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion[Pubmed:30046386] |
| Advances in Clinical and Experimental Medicine | Fibulin-3 and other cartilage metabolism biomarkers in relationship to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients treated with …[68362.pdf] |
| PLoS One | Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals[Pubmed: 30946771] |